Irinotecan in Treating Patients With Recurrent or Refractory Non-Hodgkin's Lymphoma
Status:
Completed
Trial end date:
2004-07-30
Target enrollment:
Participant gender:
Summary
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so
they stop growing or die.
PURPOSE: Phase II trial to study the effectiveness of irinotecan in treating patients with
recurrent or refractory non-Hodgkin's lymphoma.